-
1 week ago | 
aei.org | Howard Husock |Marc Thiessen |Michael Strain |Benedic Ippolito
Op-Ed To survive, Public Broadcasting Must Change. Here’s How.
-
1 month ago | 
aei.org | Scott Gottlieb |James Pethokoukis |David Shaywitz |Benedic Ippolito
Press CNBC Discussing the impact of President Trump’s policies on life science investment and innovation: Gottlieb on CNBC’s ‘Squawk Box’ Article How to Stop the Shift of Drug Discovery from the US to China Press Discussing the new Trump Administration and US health policy: Gottlieb on CNBC’s ‘Special Report’ Press CNBC Discussing the GLP-1 Drug Trade and Developments: Gottlieb on CNBC’s “Fast Money” Article Will the Anti-Obesity Wonder Drugs Work Wonders for the US Economy? Press CNBC...
-
2 months ago | 
aei.org | Frederick M. Hess |Robert Doar |Benedic Ippolito |Amitabh Chandra
The first 100 days of President Donald Trump’s second term have featured a torrent of education activity. President Trump moved to abolish the US Department of Education, slashing its workforce and yanking hundreds of millions of dollars in grants. He issued executive orders expanding school choice and demanding changes in how institutions manage gender, antisemitism, and diversity, equity, and inclusion.
-
2 months ago | 
aei.org | Frederick M. Hess |Naomi Schaefer Riley |Robert Doar |Benedic Ippolito
In the early months of the second Trump administration, conservative frustration with universities has fueled a furious burst of activity. President Donald Trump has slashed the US Department of Education and federal education research, sought to squeeze overhead rates on National Institutes of Health grants, and issued executive orders on gender, antisemitism, and diversity, equity, and inclusion on college campuses.
-
Feb 6, 2025 | 
aei.org | Amitabh Chandra |Benedic Ippolito |Daniel Cox |Brad Wilcox
Federal policy can significantly alter drugmakers’ incentives, yet there is substantial debate about how various proposals will affect the development of new drugs. At this event, experts will present the latest research on how drug development responds to policy changes—including those introduced by the Inflation Reduction Act—and what that means for coming policy debates.
-
Jan 7, 2025 | 
aei.org | Benedic Ippolito |Julia Cataneo
The Biden Administration has issued a new rule that bans all medical bills from consumer credit reports, marking the culmination of years of policy efforts. While the rule stands to benefit some consumers, policymakers should be attentive to responses by lenders and health care providers that could undercut policy goals. The new rule, announced by the Consumer Financial Protection Bureau, is motivated by the concern that medical bills may not always reflect creditworthiness.
-
Sep 10, 2024 | 
aei.org | Benedic Ippolito
Health Affairs‘ Editor-in-Chief Alan Weil interviews Benedic Ippolito of American Enterprise Institute about his recent paper exploring how expanding Medicare coverage of anti-obesity medicines could result in increased annual spending.
-
Sep 3, 2024 | 
aei.org | Benedic Ippolito
On Tuesday, August 27, a virtual Journal Club event was held examining the costs of allowing Medicare coverage of anti-obesity medicines. Anti-obesity medicines are the newest class of blockbuster drugs. With drugs like Wegovy and other GLP-1s on the market, a debate has emerged about access and coverage of these highly effective medicines. But these medicines come with a heavy price tag.
-
Aug 15, 2024 | 
aei.org | Benedic Ippolito |Joseph Levy
The introduction of highly effective anti-obesity drugs, such as Wegovy, has prompted debate over Medicare’s prohibition on coverage of such products. In this study, we estimated the costs of allowing Medicare coverage of anti-obesity medications. Our analysis incorporated data on drug costs, real-world adherence rates, and potential changes to other health care spending.
-
Jul 29, 2024 | 
aei.org | Benedic Ippolito
Site Neutrality means equal payments for equivalent health care services regardless of the setting in which they are furnished. Medicare typically pays more for a medical treatment delivered at a hospital outpatient department than it does when it is delivered in a doctor’s office. One negative consequence of this disparity: hospitals often acquire physician practices to raise prices without increasing the quality of service.
